A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, Sept. 04, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the result of a multicenter analysis of outcomes in patients with intrahepatic...
NEW YORK, Aug. 28, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an...
NEW YORK, Aug. 27, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic...
Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019 NEW YORK, Aug. 23, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Reminder of August 27, 2018 Deadline NEW YORK, Aug. 22, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday...
NEW YORK, Aug. 21, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the first patient has been enrolled under the amended protocol for its...
Stanford University Medical Center First Location to Begin Enrollment Under Single Arm Protocol NEW YORK, Aug. 20, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
NEW YORK, Aug. 17, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief...
NEW YORK, Aug. 15, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June 30, 2018. Highlights from the second quarter of...
NEW YORK, Aug. 06, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday,...